Percheron Therapeutics CEO James Garner talked with Proactive about the company’s transformation over the past year and the clinical progress of its lead asset, HMBD-002.
Garner said the business had emerged from a challenging period as a “stronger company,” supported by a highly credentialed team and a promising oncology asset. He highlighted the acquisition and development of HMBD-002, describing it as the result of an “exhaustive search” earlier in the year.
The key moment for the company came with the October data readout from its Phase 1 trial of HMBD-002. Garner noted, “We’ve got, in my view, one of the safest cancer drugs I’ve ever worked on.” He added that the trial showed signs of patient benefit, which is rare at the Phase 1 stage.
The company ended the third quarter with $5.70 million in cash and expects an R&D tax rebate in the coming year. Garner said this gives them at least four quarters of runway and that while further funding may eventually be needed, it will be modest and not immediate.
Garner also discussed the competitive landscape for Vista inhibitors. He said other players had exited due to safety concerns or financial constraints, positioning Percheron with “the most advanced Vista inhibitor in the global clinical pipeline.”
Looking ahead, the focus is on progressing HMBD-002 into Phase 2 trials, with multiple milestones planned for 2026. While emphasizing the strength of the current asset, Garner said the company would also look to diversify its pipeline over the longer term.
He acknowledged investor frustration at the share price not yet reflecting the company’s transformation but believes “that will come” as progress becomes more visible.
For more updates from Percheron Therapeutics and other interviews, visit Proactive’s YouTube channel. Don’t forget to like this video, subscribe to the channel, and turn on notifications to stay informed.
#PercheronTherapeutics #JamesGarner #HMBD002 #BiotechStocks #CancerResearch #ImmunoOncology #ClinicalTrials #ASXBiotech #DrugDevelopment #OncologyPipeline #Phase1Trial #CancerTreatment